UK may switch ipratropium combination

26 February 2015 - Deborah Wilkes

Archived

Novartis Consumer Health is seeking to switch its Otrivine Extra Dual Relief Nasal Spray, which contains xylometazoline hydrochloride and ipratropium bromide, from prescription-only to pharmacy (P) status in the UK.

Click tags below for more information on topics:

MHRA

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: